When Is Immunotherapy Considered for Allergic Rhinitis? The Steps Before Allergy Shots

The tissue box has migrated. It used to live in the bathroom; now there is one on the nightstand, one in the car, one in the bag that goes to the office. She has used the nasal spray her doctor suggested, more or less faithfully, and the allergy tablet on top of that. Some mornings are fine. Most of late spring is not.

At some point a friend, or a search result, mentions allergy shots. The idea is appealing and slightly alarming at once: years of injections, for a runny nose? So the question forms the way it forms for many people. Is immunotherapy for allergic rhinitis something I should be asking about, or something reserved for people far worse off than me?

The honest answer is that it sits at a particular point on a well-marked path. This article walks that path in order, from the first test to the last maintenance visit, without skipping the steps that are supposed to come first.

How does immunotherapy for allergic rhinitis actually work?

Allergic rhinitis is the medical name for hay fever: inflammation of the nasal lining triggered by an allergen, a normally harmless airborne protein such as pollen, dust mite waste, mold spores or pet dander. In a person with allergies, the immune system has produced IgE, a type of antibody that sits on mast cells in the nose and eyes and treats that protein as a threat. Contact releases histamine and other chemicals within minutes, and the familiar sneeze, itch and drip follow.

Every other treatment in this article works downstream of that event. A nasal steroid calms the inflammation; an antihistamine blocks the histamine already released. Allergen immunotherapy is different in kind. It delivers small, steadily increasing amounts of the specific allergen on a controlled schedule so the immune system learns to tolerate what it has been overreacting to. Over months, the balance shifts: regulatory immune cells dampen the response, blocking antibodies of a class called IgG begin to intercept the allergen before it reaches IgE, and the nose becomes measurably less reactive on exposure.

That is why allergists describe it as disease-modifying rather than symptom-masking, and why it is the only approach that can keep working after the course ends. It is also why it demands patience. Retraining an immune response is slow, the course runs for years, and the effect is specific to the allergens included. A person treated for grass pollen is not thereby protected from cats.

Two routes exist: injections given in a clinic, known as subcutaneous immunotherapy or allergy shots, and tablets that dissolve under the tongue, known as sublingual immunotherapy. Both aim at the same immune change through different doors.

Step one: confirming the sneezing really is allergic

Not every stuffy nose is allergic, and this is the first place the path can fork. Nonallergic rhinitis, a nasal lining that overreacts to temperature, smoke, perfume or spicy food without any IgE involvement, produces similar congestion and drip but does not respond to immunotherapy at all. Chronic sinusitis, nasal polyps, a deviated septum and rebound congestion from overused decongestant sprays can all masquerade as hay fever.

So the first step is a careful history. When do symptoms come and go? Do they follow the tree, grass and weed pollen seasons, or run year-round, which points toward dust mites, mold or pets? Do the eyes itch? Is there wheeze, cough or a family history of asthma or eczema? Timing alone often narrows the field considerably.

Testing then confirms what the history suggests. A skin prick test places tiny amounts of common allergens on the forearm or back and looks for a raised, itchy bump within about 15 to 20 minutes, according to Mayo Clinic. A blood test measures allergen-specific IgE instead and is useful when skin testing is impractical, for example in people with widespread eczema or those who cannot pause antihistamines beforehand.

A positive test alone is not a diagnosis. Plenty of people react on skin testing to allergens that never bother them in real life. What matters is the match between a positive result and symptoms that appear on exposure. Immunotherapy is built around that match: the extract or tablet contains only the allergens judged clinically relevant, so getting this step right shapes everything that follows.

Step two: reducing exposure, and what the evidence says it can do

Once the trigger is named, the next step sounds simple: avoid it. In practice the results are mixed, and being honest about that saves frustration.

For pollen, the NHS suggests practical measures: keeping windows shut when counts are high, showering and changing clothes after time outdoors, wearing wraparound sunglasses, and applying a barrier balm around the nostrils to trap pollen. None of these replaces treatment, but together they lower the daily load.

For dust mites, the evidence is humbler than the marketing. Encasing mattresses and pillows in allergen-impermeable covers, washing bedding in hot water weekly and lowering indoor humidity can reduce mite allergen levels, yet systematic reviews have struggled to show that any single measure clearly improves symptoms on its own. Combined strategies fare somewhat better.

For pets, the only measure with consistent effect is removing the animal from the home, which many families reasonably decline. Keeping the pet out of the bedroom and running a HEPA filter reduce, but do not eliminate, airborne dander.

Mold responds to fixing the source: leaks, damp basements, poorly ventilated bathrooms.

Clinicians insist on this step not because they expect it to solve the problem but because it establishes a baseline. If exposure has genuinely been reduced and symptoms persist, the picture is clearer. Exposure control also continues to matter during immunotherapy, since a heavy allergen load can worsen reactions on injection days. Think of it as lowering the volume in the room before trying to retune the instrument.

Step three: the medicines usually tried first, and why they seem to fail

Most people reach the immunotherapy conversation after medicines have been tried, and the details of how they were tried matter enormously.

Intranasal corticosteroid sprays are the cornerstone of guideline-based treatment for moderate or persistent allergic rhinitis. They work by reducing inflammation in the nasal lining rather than blocking a single chemical, which is why they help congestion as well as sneezing. Their weakness is timing: they build effect over days to a couple of weeks of daily use and do little when sprayed only on bad days. Technique matters too. Aiming the nozzle slightly outward, away from the septum, reduces nosebleeds and improves delivery.

Oral antihistamines block histamine at its receptor and act within an hour or two. Newer, less-sedating types are preferred. They are good at itch, sneeze and drip and weaker on blockage. Antihistamine nasal sprays and eye drops address local symptoms quickly.

Saline rinses physically wash allergen and mucus from the nose and can be used alongside anything else. Leukotriene modifiers, a separate class, are sometimes added when asthma coexists. Decongestant sprays give dramatic short-term relief but cause rebound congestion with continued use, so they are generally limited to a few days.

When a clinician hears “the sprays didn’t work,” the first questions are how long, how regularly and how they were used. A great many “treatment failures” are, on closer look, treatment trials that never reached a fair test. Only once a steroid spray, often combined with an antihistamine, has been used properly through a full season does the door to immunotherapy usually open. Any change to these medicines belongs with the prescriber.

When is immunotherapy for allergic rhinitis considered?

The threshold is not a single symptom score but a convergence of circumstances. Allergists generally look for several of the following.

First, confirmed sensitization that matches the story: a positive skin or blood test to an allergen the person is clearly exposed to when symptoms flare. Without this, there is nothing to treat.

Second, symptoms that still interfere with sleep, work, school or exercise despite consistent, correctly used medicines and reasonable avoidance. “Interfere” is the operative word. Someone who sneezes a few times on high-pollen mornings and otherwise feels well is rarely a candidate, whatever the test shows.

Third, medicine problems rather than medicine failure: drowsiness, nosebleeds, or simply a strong wish not to take daily medicines for decades. Wanting to reduce long-term reliance on medication is a legitimate reason and appears in guideline discussions.

Fourth, the shape of the allergy. Year-round exposure, several overlapping seasons, or coexisting allergic conjunctivitis or mild allergic asthma tips the balance toward a treatment that changes the underlying response. In children with allergic rhinitis, some studies suggest immunotherapy may lower the chance of later developing asthma, though the evidence is mixed and long-term data remain limited.

Fifth, and easily overlooked, the capacity to commit. A course lasts three to five years, according to Mayo Clinic, and the early phase involves frequent clinic visits. Someone about to move abroad, or who cannot reliably attend, may be advised to wait.

No single factor is decisive. The treating team weighs them together with the person’s health history, and the decision to proceed is made with the patient rather than triggered automatically by a test result.

Who qualifies for allergy shots, and who is usually asked to wait?

Typical candidates are older children, teenagers and adults with confirmed IgE-mediated allergy to airborne allergens whose symptoms remain bothersome after steps two and three. Sensitization to a small number of relevant allergens makes a cleaner target than reactions to everything on the panel, though multi-allergen mixes are used.

Several groups are usually asked to wait, or steered toward a different route.

• Young children. Mayo Clinic notes that allergy shots are not usually recommended below about age five, partly because small children struggle to describe early reaction symptoms and partly because the commitment is hard to sustain.
• People with uncontrolled or severe asthma. Poorly controlled airways raise the risk of a serious reaction, so asthma is stabilized first and checked at each visit.
• Pregnancy. Immunotherapy is generally not started during pregnancy because of the reaction risk during build-up, though a stable maintenance course may sometimes be continued under supervision.
• Certain heart conditions or medicines. Some drugs, including a class called beta blockers, can make an allergic reaction harder to treat, which shifts the risk calculation. This is discussed with the prescriber; no one should alter such medicines on their own.
• Anyone unwell on the day. Fever, an asthma flare or active symptoms on a heavy pollen day can lead to a postponed injection.

Older adults are not excluded by age, but coexisting conditions weigh more heavily in the assessment. People with severe eczema, immune deficiency or autoimmune disease are evaluated case by case.

Sublingual tablets carry their own criteria: they exist for a limited set of allergens, and the first dose is taken under observation. Either way, the eligibility judgment sits with the allergist, who can see the whole picture.

Allergy shots vs sublingual immunotherapy for allergies: how the two routes compare

The mechanism is shared; the logistics differ, and for many people the logistics decide it. Here is how the two routes typically line up, drawing on Mayo Clinic and MedlinePlus descriptions.

Feature	Allergy shots (subcutaneous)	Sublingual tablets
How given	Injection under the skin of the upper arm	Tablet dissolved under the tongue
Where	Clinic, every time	First dose in clinic, then at home
Allergens covered	Wide range; mixes tailored to test results	Limited set, chiefly certain grass pollens, ragweed and dust mite
Visit pattern	Frequent during build-up, spaced out in maintenance	Daily at home, with periodic clinic reviews
Observation	About 30 minutes after each injection	After the first dose only
Typical reactions	Local swelling and itch at the site	Mouth itching or tingling, throat irritation
Serious reaction risk	Rare; almost always within the observation window	Very rare; emergency epinephrine usually prescribed as a precaution
Course length	Three to five years	Three years or more, often started before the season

Shots suit people allergic to several things, or to allergens no tablet covers, and those who prefer a clinician handling each step. Tablets suit people with a single dominant allergy on the covered list, a dislike of needles, or a schedule that cannot accommodate regular visits.

Neither route is universally better. Head-to-head trials are few; the evidence base for shots is longer and broader, while tablets have strong trial data for the allergens they cover. The right route is the one matching the person’s allergen profile, health history and realistic ability to complete the course.

What actually happens at a shot visit, and what the first months look like

A shot visit is undramatic by design. A nurse asks about symptoms since the last injection, any reaction at the previous site and, for people with asthma, how their breathing has been; some clinics check peak flow. The extract is drawn from a vial prepared to the allergist’s prescription and injected just under the skin of the upper arm. Then comes the part people underestimate: a wait of about 30 minutes in the clinic, according to Mayo Clinic, because serious reactions, when they occur, almost always begin in that window.

The build-up phase, during which the amount of allergen increases gradually, typically takes three to six months per Mayo Clinic. Visits are frequent, and this is the stretch where drop-out is most common. A red, itchy, swollen patch at the injection site is expected and usually settles within a day; a cool compress helps.

Once the target amount is reached, maintenance begins and visits space out considerably. The whole course generally runs three to five years.

During the early months, most people notice no change in their allergies, and that is normal. Regular medicines continue as prescribed; immunotherapy is added to them, not swapped for them. Mayo Clinic notes that symptoms often improve during the first year and continue improving in the second, at which point the treating team may discuss easing back on daily medicines. That decision is theirs.

Practical habits help: avoid strenuous exercise for a couple of hours before and after an injection, since raised blood flow can speed absorption; mention any new medicine or pregnancy; and never take an injection at home. Sublingual tablets follow a different rhythm, with the first tablet observed in clinic and the rest taken daily at home.

What are the downsides of allergy immunotherapy?

Every honest explainer owes readers this section, because the trade-offs are real.

Time is the largest. Frequent visits for months, then years of maintenance, each with a half-hour wait. For someone with two jobs or a long commute, that alone can make the treatment impractical, and unfinished courses deliver less.

Local reactions are common and expected: redness, swelling and itch at the site, sometimes the size of a coin or larger, lasting hours to a day. Sublingual tablets cause oral itching, lip swelling or throat irritation in many users, usually easing over the first weeks.

Systemic reactions are the reason for the clinic wait. They range from hives, sneezing and wheeze to, rarely, anaphylaxis, a whole-body reaction involving breathing difficulty and a drop in blood pressure that requires immediate epinephrine. MedlinePlus and Mayo Clinic both describe these as uncommon and note they usually appear within 30 minutes of an injection. Risk rises with uncontrolled asthma, during build-up, and on days of heavy natural exposure.

Uncertainty of response is the downside least often discussed. Systematic reviews show that immunotherapy, on average, reduces symptom scores and medicine use more than placebo, but averages hide variation. Some people improve substantially; some modestly; a minority not at all. No test predicts which group a person will fall into before starting.

Then there is scope. Treatment covers only the allergens included. New sensitivities can develop, and symptoms can return after the course ends, sometimes years later.

Immunotherapy also adds to, rather than replaces, the daily routine for a long stretch. The burden is front-loaded and the payoff is slow. Weighing that trade-off is the heart of the conversation with the allergist.

How long does allergy immunotherapy take, and how long does relief last?

This is the question that decides most choices, so it deserves the evidence rather than a slogan.

The course itself is measured in years. Mayo Clinic gives three to six months for build-up and three to five years overall for allergy shots; sublingual tablets are typically continued for at least three years. Stopping early tends to forfeit the lasting benefit, which is why allergists ask about commitment before the first injection.

Improvement arrives gradually. Some people notice a milder season within the first year; more commonly the difference becomes clear by the second. Because seasons vary, one lighter spring can be luck rather than treatment, and clinicians usually judge response over two or more pollen seasons before drawing conclusions.

As for durability, this is where immunotherapy stands apart. Follow-up studies of grass-pollen immunotherapy have found symptom benefit persisting for several years after a completed three-year course, and the effect tends to be larger and longer with longer courses. That persistence is what “disease-modifying” means in practice. It does not mean the allergy is gone. Sensitization on testing often remains, symptoms can gradually return, and some people choose a second course later in life.

The evidence quality is moderate rather than airtight. Trials are often industry-funded, of variable length, and rely on symptom diaries; long-term follow-up beyond a decade is scarce. Guideline bodies nonetheless rate immunotherapy as effective for appropriately selected patients, precisely because the pattern of benefit is consistent across many studies.

A fair summary: expect a slow start, a clearer difference by year two, and a good chance, not a certainty, that the benefit outlasts the treatment.

What is the best age for allergy immunotherapy?

There is no single best age, but there are ages that shift the calculation.

Children. Allergy shots are generally not started below about age five, per Mayo Clinic. Younger children find frequent injections distressing and cannot reliably report the early tingling, itch or tightness that signals a reaction. From school age onward, children are often considered good candidates: their allergic disease is usually simpler, with fewer sensitizations, and there is interest in whether early treatment reduces the later risk of asthma. Some studies suggest it may; the evidence is not conclusive, and families should hear this as a hope rather than a promise. Sublingual tablets are approved for children above a specified age for some allergens, which removes the needle problem for those allergens.

Teenagers and young adults. This is often the age of greatest disruption, with exams, sport and new jobs, and also the age of poorest attendance. Practical support for keeping appointments can matter as much as the treatment.

Adults. Most immunotherapy is given to adults, and the evidence base is strongest here. There is no upper limit, but coexisting heart or lung disease, medicines that complicate reaction management, and the years of commitment weigh more heavily later in life.

Older adults. Allergic rhinitis can persist or emerge in later decades. Immunotherapy remains an option, assessed individually against overall health.

Rather than asking what age is best, a more useful question is what stage the allergy has reached. A person whose symptoms have escalated, whose seasons have lengthened, or who has developed eye or chest symptoms alongside the nose may benefit from acting before the picture becomes more complex, whatever their birthday says.

What people often get wrong about immunotherapy for hay fever

Myth: allergy shots are a last resort for severe cases. They are a later step, not a last one. Guidelines position immunotherapy for people with moderate to severe symptoms despite medicines, but “severe” is defined by impact on life, not by how dramatic the sneezing looks.

Myth: once you finish, the allergy is gone permanently. Benefit often persists for years after a completed course, yet sensitization usually remains detectable and symptoms can creep back. The realistic goal is lasting control, not erasure.

Myth: it works quickly. Months of build-up pass before any change is expected, and the first season on treatment is often unchanged. People who quit in month four because nothing happened have not tested the treatment.

Myth: allergy drops bought online are the same as clinic immunotherapy. Sublingual tablets used in mainstream practice have gone through regulatory approval for specific allergens. Unregulated drops, and the tests marketed alongside them, lack that evidence and should not be assumed equivalent.

Myth: you can stop your other medicines as soon as you start. Immunotherapy is layered onto existing treatment. Any tapering happens later, on the treating team’s advice.

Myth: it treats any allergy. Airborne allergens are the target here. Food allergy immunotherapy is a separate, specialized field with different protocols and risks, and immunotherapy does not address nonallergic rhinitis at all.

Myth: local honey does the same thing. Honey contains mostly flower pollen carried by bees, not the wind-borne tree and grass pollen that causes hay fever. Trials have not shown meaningful benefit.

Myth: a positive test means you need shots. A positive test means you are sensitized. Whether that sensitization drives your symptoms, and whether those symptoms warrant a multi-year course, are clinical judgments made with the allergist.

Questions to ask your care team before starting

A good consultation about immunotherapy is a two-way interview. These questions tend to surface the information that matters.

• Which specific allergens will be included, and how confident are you that each one drives my symptoms?
• Have I genuinely given the nasal steroid spray and antihistamine a fair trial, and is my technique correct?
• Would shots or sublingual tablets suit my allergen profile better, and why?
• What visit pattern should I expect in the build-up phase, and roughly how long will the full course run for me?
• What reactions are normal at the injection site, and what would you want me to report?
• Is my asthma, if I have it, well enough controlled to start?
• Do any of my current medicines or health conditions change the risk, and who should review them?
• What should I do if I miss appointments or travel for an extended period?
• When would you expect to judge whether the treatment is working, and how will we measure that?
• If I improve, when and how would we discuss easing back on daily medicines?
• What happens if I want to stop early?

Bring a symptom diary, or even a few dated notes from the past season; these are more useful than memory. Bring a list of everything you take, including over-the-counter products and supplements. If you are planning a pregnancy, say so, since it affects timing.

Notice what the good answers have in common: they are specific to you, they acknowledge uncertainty, and they leave room for you to decline. An allergist who says “we’ll see how you respond over two seasons” is being more honest than one who promises a symptom-free spring.

When to call your doctor

Most reactions to immunotherapy are local and mild, but a small number need prompt action, and knowing the difference in advance is part of safe treatment.

Call emergency services immediately if, after an injection or a sublingual dose, you notice any of the following, alone or together: difficulty breathing, wheezing or chest tightness; swelling of the lips, tongue or throat, or trouble swallowing; widespread hives or flushing; dizziness, faintness or a racing heart; or a sense of impending doom, which people who have experienced anaphylaxis describe consistently. If you carry an epinephrine auto-injector, use it as you have been taught, then call. These reactions almost always begin within about 30 minutes of an injection, which is why the clinic wait exists, but delayed reactions occasionally occur, so treat such symptoms in the hours afterward the same way.

Contact your allergy clinic the same day, before the next dose, if you have a large swelling at the injection site that keeps growing or lasts more than a day; sneezing, itchy eyes or a cough that starts within an hour of a shot; worsening asthma; a new fever or illness; or if you have started a new medicine, learned you are pregnant or missed several appointments. These are not emergencies, but each may change how the next dose is given.

Outside of immunotherapy itself, arrange a routine appointment if nasal symptoms are one-sided only, if there is blood in nasal discharge without an obvious cause, if facial pain or pressure lasts more than ten days, or if you lose your sense of smell. These point away from simple allergy and toward something that deserves a look.

Every decision along this path, from testing to tapering, sits with the treating team. This article is a map, not the guide walking beside you.

Frequently asked questions

What are the downsides of allergy immunotherapy?

The main downsides are time, local reactions and uncertain response. Frequent clinic visits during build-up and years of maintenance are a real burden, injection-site swelling and itch are common, and sublingual tablets often cause mouth itching early on. Serious whole-body reactions are rare but possible, which is why shots are given under observation. Some people respond strongly, others modestly, and no test predicts which group you will be in.

How expensive is immunotherapy for allergies?

This article does not cover costs, which vary widely with insurance coverage, the route chosen, the number of allergens included and how long the course runs. The clinic’s administrative team and your insurer can give figures specific to your situation. What is worth weighing alongside cost is the time commitment: frequent visits in the early months and several years of maintenance, each with a wait after the injection.

Is there a permanent fix for allergic rhinitis?

No treatment makes the allergy disappear for good, but immunotherapy comes closest to long-lasting control. Follow-up studies show benefit persisting for several years after a completed course, while sensitization often remains on testing and symptoms can gradually return. Medicines and avoidance manage symptoms while they are used; immunotherapy changes how the immune system responds. The realistic goal is durable control rather than erasure, and the allergist can say what is plausible for you.

What is the best age for allergy immunotherapy?

There is no single best age. Allergy shots are generally not started below about age five, according to Mayo Clinic, because young children cannot reliably report early reaction symptoms. School-age children, teenagers and adults of any age are considered, with older adults assessed against coexisting conditions and medicines. A more useful question than age is stage: escalating symptoms, lengthening seasons or new eye and chest involvement may argue for acting sooner.

How long does allergy immunotherapy take to work?

Expect a slow start. The build-up phase alone typically takes three to six months, and most people notice little change until the first year is well under way; Mayo Clinic notes improvement often becomes clearer in the second year. Clinicians usually judge response over two or more pollen seasons because seasons vary naturally. The full course runs three to five years, and stopping early tends to forfeit the lasting benefit.

Is sublingual immunotherapy for allergies as effective as shots?

For the allergens they cover, sublingual tablets have strong trial evidence for reducing symptoms and medicine use, and they avoid needles and most clinic visits. Shots have a longer, broader evidence base and can be tailored to many allergens at once. Direct head-to-head trials are few, so neither is proven universally better. The choice depends on your allergen profile, health history and ability to complete the course, decided with your allergist.

Are allergy shots for hay fever worth it if my season lasts only a few weeks?

Often not, and allergists weigh this carefully. A short season that responds to a properly used nasal steroid spray and antihistamine rarely justifies a multi-year course of injections. Immunotherapy tends to make more sense when seasons are long or overlapping, symptoms persist despite good medicine use, side effects are troublesome, or eye and chest symptoms are developing. Your care team can help judge whether the burden matches the likely benefit.

Can I start allergy shots during pregnancy?

Immunotherapy is generally not started during pregnancy because the build-up phase carries the highest reaction risk, and a serious reaction could affect both mother and baby. Someone already on a stable maintenance course may sometimes continue under supervision, at the treating team’s discretion. If you are planning a pregnancy, mention it before starting so the timing can be planned; if you become pregnant during treatment, tell the clinic before your next visit.

Do allergy shots hurt?

The injection itself is brief and shallow, given just under the skin of the upper arm with a fine needle, and most people describe a quick pinch. The more noticeable sensation is afterward: a red, itchy, sometimes swollen patch at the site that usually settles within a day. A cool compress helps. Children often find the routine easier than expected once the first few visits are behind them.

What happens if I miss appointments or travel for a while?

Gaps matter, especially during build-up, because tolerance to the increasing amounts of allergen fades when doses are spaced too far apart. Depending on how long the gap was, the clinic may repeat a step or restart part of the build-up to keep the next injection safe. Tell the team about planned travel in advance and never try to make up missed doses on your own; the adjustment is theirs to make.

References

• MedlinePlus: Allergic rhinitis
• NHS: Hay fever
• Cleveland Clinic: Allergic Rhinitis (Hay Fever)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.